Hematolymphoid lesions of the breast

Semin Diagn Pathol. 2017 Sep;34(5):462-469. doi: 10.1053/j.semdp.2017.05.007. Epub 2017 May 28.


Hematolymphoid malignancies of the breast are most commonly neoplasms of mature B-lymphocytes, and may arise as a primary disease or by secondary involvement of a systemic disease. Primary breast lymphomas (PBL) account for 0.04-0.5% of breast malignancies, less than 1% of all non-Hodgkin's lymphomas (NHL), and less than 5% of extranodal lymphomas (Lakhani et al., 2012; Swerdlow et al., 2008; Joks et al., 2011; Barişta et al., 2000; Giardini et al., 1992; Brogi and Harris, 1999; Topalovski et al., 1999).1-7 Secondary breast lymphomas (SBL) are also rare, with an estimated annual incidence of 0.07% (Domchek et al., 2002; Talwalkar et al., 2008).8,9 Recognition of breast lesions as hematolymphoid is critical to distinguish them from other entities that can occur in the breast.

Keywords: Anaplastic large cell lymphoma; Breast; Breast lymphoma; Burkitt lymphoma; Chloroma; Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Granulocytic sarcoma; Hematolymphoid neoplasms; High grade B-cell lymphoma; Lymphoma; Marginal zone lymphoma; Myeloid sarcoma; Primary breast lymphoma; Secondary breast lymphoma; Small lymphocytic lymphoma.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis
  • Biopsy
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / pathology*
  • Diagnosis, Differential
  • Female
  • Humans
  • Immunohistochemistry
  • Incidence
  • Lymphoma / chemistry
  • Lymphoma / epidemiology
  • Lymphoma / pathology*
  • Predictive Value of Tests
  • Prognosis


  • Biomarkers, Tumor